Leukemia nursing: AML, ALL, CML, and CLL reference for nursing students

Leukemia is the uncontrolled proliferation of abnormal white blood cell precursors in the bone marrow. As the marrow fills with malignant cells, production of normal red blood cells, platelets, and functional white cells falls — resulting in the triad of anemia, thrombocytopenia, and immunosuppression that defines the clinical syndrome. There are four main types, divided by cell lineage (myeloid vs. lymphoid) and disease tempo (acute vs. chronic). Understanding the distinguishing features of each type is fundamental to nursing assessment and NCLEX performance.

Pathophysiology: why leukemia causes pancytopenia

In all leukemia types, the core problem is the same: malignant white cell precursors proliferate without normal regulatory control, crowding out the normal bone marrow elements that produce red blood cells, platelets, and functional white cells.

Blast cell accumulation in the marrow physically displaces erythroid precursors (causing anemia) and megakaryocytes (causing thrombocytopenia). The leukemic white cells, despite being abundant in number, are functionally defective — they cannot mount an effective immune response, leaving patients vulnerable to infection. This combination — anemia, thrombocytopenia, and immunosuppression from normal marrow replacement — is pancytopenia, and it underlies the three cardinal symptom clusters of leukemia: fatigue and pallor (anemia), bleeding and bruising (thrombocytopenia), and recurrent infections (neutropenia).

In acute leukemias, this process is rapid and overwhelming. In chronic leukemias, marrow replacement occurs gradually, and patients may have near-normal counts for years before symptoms emerge. Understanding this tempo difference guides clinical assessment: the acute leukemia patient often presents in crisis; the chronic leukemia patient may be found incidentally on a routine CBC.

For the nursing management of anemia resulting from marrow replacement, see the anemia nursing reference. For thrombocytopenia management when platelets are suppressed, see thrombocytopenia nursing reference.

AML: acute myeloid leukemia

AML is the most common acute leukemia in adults, accounting for approximately 80% of acute leukemia cases in this population. The median age at diagnosis is around 68 years. It arises from myeloid precursors — the cells that normally mature into granulocytes, monocytes, or erythrocytes — and is defined by the presence of ≥20% myeloid blasts in the peripheral blood or bone marrow.

Pathognomonic finding: Auer rods

The single most important AML finding on NCLEX is the Auer rod — needle-like, azurophilic cytoplasmic inclusions visible on Wright-Giemsa stain of the peripheral blood smear. Auer rods are found only in myeloid blasts, never in lymphoid cells. Their presence on a smear in a patient presenting with pancytopenia and circulating blasts is diagnostic for AML (not ALL). Auer rods are particularly abundant in acute promyelocytic leukemia (APL, AML-M3 subtype).

APL and DIC risk

The APL subtype carries a critical complication that every nurse must recognize: disseminated intravascular coagulation (DIC). APL cells contain abnormal granules that release tissue factor, triggering widespread clotting cascade activation and paradoxical simultaneous bleeding and thrombosis. DIC risk is highest at diagnosis and during induction chemotherapy as blast cells lyse. For the full DIC nursing framework, see the oncology nursing reference.

Treatment of APL uses all-trans retinoic acid (ATRA) — a differentiation agent that forces the leukemic promyelocytes to mature rather than proliferate. Early initiation of ATRA at diagnosis has dramatically reduced DIC-related mortality by clearing blasts before cytotoxic chemotherapy is started. Arsenic trioxide is added to ATRA in standard frontline APL treatment.

AML treatment: the 7+3 regimen

Induction chemotherapy for non-APL AML uses the 7+3 regimen: cytarabine given as a 7-day continuous IV infusion, combined with daunorubicin (or idarubicin) on days 1 through 3. The goal is to achieve a complete remission — reducing marrow blasts below 5%. This requires profound, intentional bone marrow ablation, leaving the patient in severe pancytopenia for 2–4 weeks while the marrow recovers. This period demands intensive nursing management.

Nursing priorities during AML induction:

• Monitor CBC daily; report ANC <500/µL, platelet counts trending toward transfusion thresholds
• Assess cardiac function at baseline; anthracyclines (daunorubicin, idarubicin) are cardiotoxic — monitor for arrhythmias and CHF signs
• Mucositis management: cytarabine causes severe oral mucositis; provide oral rinses, soft diet, pain assessment
• Monitor for tumor lysis syndrome (TLS) during early chemo — see the TLS section below
• Bleeding precautions for thrombocytopenia; restrict activities with platelet count <50,000/µL
• Neutropenic precautions for ANC <500/µL (see neutropenic precautions section)

Consolidation therapy follows induction to eliminate residual disease. High-dose cytarabine is standard; allogeneic stem cell transplant is offered to eligible patients with high-risk disease.

ALL: acute lymphoblastic leukemia

ALL is the most common cancer in children, accounting for approximately 75% of pediatric leukemia diagnoses. It arises from lymphoid precursors — either B-cell or T-cell lineage. The peak incidence in children is ages 2–5 years, with a favorable prognosis when treated with modern pediatric protocols (cure rates 80–90% in children). Adult ALL carries a lower cure rate and requires more aggressive treatment.

Philadelphia chromosome in adult ALL

The Philadelphia chromosome t(9;22) — the BCR-ABL fusion gene that defines CML — is present in approximately 25% of adult ALL cases. This is a critical NCLEX distinction: while Philadelphia chromosome is primarily associated with CML, it also appears in adult ALL where it confers a worse prognosis in the absence of tyrosine kinase inhibitor therapy. Ph-positive adult ALL is treated with chemotherapy combined with a TKI (typically dasatinib or ponatinib).

CNS involvement and prophylaxis

Lymphoblasts readily penetrate the blood-brain barrier, making the central nervous system a sanctuary site for leukemic cells. CNS prophylaxis is a mandatory component of all ALL treatment protocols, delivered via intrathecal chemotherapy (methotrexate ± cytarabine injected directly into the cerebrospinal fluid via lumbar puncture) and/or cranial radiation in high-risk patients. Without CNS prophylaxis, relapse rates in the CNS approach 50%.

Nursing assessment for CNS leukemia includes monitoring for headache, photophobia, cranial nerve palsies, papilledema, nausea, and signs of elevated intracranial pressure. Report any new neurological symptoms promptly.

L-asparaginase: mechanism and toxicities

L-asparaginase is a key agent in ALL induction and is included in nearly all pediatric and young adult ALL protocols. It depletes asparagine in the bloodstream — an amino acid that ALL cells cannot synthesize themselves (unlike normal cells). Without asparagine, leukemic cells cannot produce protein and undergo apoptosis.

L-asparaginase toxicities nurses must monitor:

Corticosteroids in ALL

Dexamethasone or prednisone is part of standard ALL induction. Steroids contribute to cytoreduction but introduce nursing concerns: hyperglycemia, mood changes (irritability, steroid psychosis), fluid retention, hypertension, and bone density loss with prolonged use. Monitor blood glucose at least every 6 hours during steroid-heavy induction phases. Educate patients and families not to abruptly discontinue steroids.

CML: chronic myeloid leukemia

CML is driven by a single molecular abnormality: the Philadelphia chromosome — a reciprocal translocation between chromosomes 9 and 22 that creates the BCR-ABL1 fusion gene. BCR-ABL1 encodes a constitutively active tyrosine kinase that drives uncontrolled granulocyte proliferation. CML is the prototypical targeted therapy success story: the discovery of imatinib (Gleevec) transformed a disease with a median survival of 3–5 years into a chronic condition managed with a daily oral pill.

Three phases of CML

CML progresses through three phases, and recognizing phase transitions is clinically important:

Key clinical finding: splenomegaly

Massive splenomegaly is the most prominent physical finding in CML and results from extramedullary hematopoiesis — the spleen taking over blood cell production as the marrow is overwhelmed. Patients may report early satiety, left upper quadrant pain, and abdominal fullness. Nurses should palpate the abdomen gently (never percuss forcefully over an enlarged spleen — splenic rupture risk) and report any rapid increase in spleen size.

Tyrosine kinase inhibitors (TKIs)

TKI therapy is first-line for chronic phase CML. Imatinib (Gleevec) was the first approved TKI and remains widely used. Second-generation TKIs (nilotinib, dasatinib, bosutinib) are used for imatinib intolerance or for higher-risk disease.

Imatinib nursing considerations: Monitor CBC (cytopenias common in early treatment), liver function tests (hepatotoxicity), fluid retention and peripheral edema, nausea (administer with food and water), and muscle cramps. The T315I resistance mutation renders all first- and second-generation TKIs ineffective; patients with this mutation require ponatinib (third-generation TKI) or transplant evaluation.

Adherence is critical — patients who take TKIs inconsistently are at risk for disease progression and resistance. Medication adherence assessment and patient education are priority nursing functions in CML outpatient care.

CLL: chronic lymphocytic leukemia

CLL is the most common leukemia in adults in the Western world. It arises from mature, functionally incompetent B-lymphocytes (CD5+/CD23+) that accumulate in the blood, bone marrow, lymph nodes, and spleen. The disease is typically indolent; many patients are diagnosed incidentally on a routine CBC and live for a decade or more without requiring treatment. Others have progressive disease requiring intervention.

Pathognomonic finding: smudge cells

On peripheral blood smear, CLL cells are extremely fragile and rupture during preparation of the slide, leaving behind nuclear remnants called smudge cells (also called Gumprecht’s shadows). Their presence on smear in a patient with absolute lymphocytosis is characteristic of CLL and high-yield for NCLEX. Note: while smudge cells are strongly associated with CLL, they are not exclusively pathognomonic (other lymphoproliferative disorders can produce them). Formal diagnosis requires flow cytometry confirming the characteristic CD5+/CD19+/CD23+ immunophenotype.

Presenting features and staging

Most CLL patients are asymptomatic at diagnosis. When symptoms occur, they reflect lymphocyte accumulation and marrow infiltration:

• Lymphadenopathy — typically non-tender, rubbery, symmetrical; cervical, axillary, and inguinal nodes most common
• Hepatosplenomegaly — from lymphocyte infiltration of liver and spleen
• B symptoms — fever, drenching night sweats, unintentional weight loss >10% body weight; when present, suggest more aggressive disease or Richter transformation
• Fatigue and anemia — from marrow replacement or autoimmune hemolytic anemia (CLL can trigger antibodies against the patient’s own RBCs)
• Recurrent infections — CLL B-cells are non-functional; hypogammaglobulinemia (decreased antibody production) leads to susceptibility to encapsulated bacteria

Staging uses the Rai classification: Stage 0 (lymphocytosis only, low risk) through Stage IV (thrombocytopenia, high risk). Early stage (Rai 0–I) = watch-and-wait; late stage (Rai III–IV) or symptomatic disease = initiate treatment.

Watch-and-wait approach

A core NCLEX concept in CLL is that early-stage asymptomatic CLL is not treated. Multiple randomized trials have shown that early intervention provides no survival benefit and adds toxicity without improving outcomes. Patients in watch-and-wait have CBC monitoring every 3–6 months. Nurses should educate patients that not receiving treatment does not mean their disease is being ignored — it reflects evidence-based management. The trigger for treatment initiation includes progressive lymphocytosis, increasing lymphadenopathy or splenomegaly, B symptoms, or cytopenias.

Richter transformation

Approximately 2–10% of CLL patients undergo Richter transformation — conversion to a highly aggressive lymphoma (most commonly diffuse large B-cell lymphoma). Clinically, Richter transformation presents with rapidly enlarging lymph nodes, systemic B symptoms, rising LDH, and constitutional deterioration in a patient with previously stable CLL. It carries a median survival of 3–6 months and represents a distinct oncologic emergency. Nurses should immediately report any sudden lymph node enlargement, new B symptoms, or rapid clinical deterioration in a patient with known CLL.

Tumor lysis syndrome

Tumor lysis syndrome (TLS) is a life-threatening metabolic emergency caused by the rapid destruction of large numbers of cancer cells — either spontaneously or in response to chemotherapy. As cells lyse, their intracellular contents (potassium, phosphate, nucleic acids) flood the bloodstream faster than the kidneys can excrete them. Four concurrent metabolic disturbances define TLS:

The memory device: three “hypers” plus one “hypo” — hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia.

High-risk patients for TLS

TLS risk is highest in patients with high tumor burden and rapidly proliferating disease:

• ALL with WBC >100,000/µL (highest risk overall)
• AML with WBC ≥100,000/µL or blast crisis in CML
• Burkitt lymphoma and diffuse large B-cell lymphoma (bulky disease)
• Any leukemia undergoing aggressive induction chemotherapy

TLS nursing management

Before chemotherapy (prevention):

• Aggressive IV hydration: 3–3.5 L/m²/day, targeting urine output ≥2 mL/kg/h; this is the single most important TLS preventive measure
• Allopurinol: xanthine oxidase inhibitor given 1–2 days prior to chemo in moderate-risk patients; prevents new uric acid formation but does not reduce existing levels
• Rasburicase: recombinant urate oxidase that converts existing uric acid to the soluble allantoin; preferred for high-risk patients due to rapid action; contraindicated in G6PD deficiency (causes hemolysis); must be given before chemo in high-risk patients

During and after chemotherapy:

• Lab monitoring every 4–6 hours during high-risk periods: potassium, phosphate, calcium, uric acid, creatinine, BUN
• Continuous cardiac monitoring during acute TLS — hyperkalemia and hypocalcemia both produce potentially fatal arrhythmias
• Strict intake and output; indwelling urinary catheter may be needed to accurately measure output
• Restrict potassium and phosphate intake; dietary consultation
• Report any decrease in urine output promptly — oliguria signals renal tubular obstruction from urate or calcium phosphate crystals; hemodialysis is indicated for severe oliguria, persistent hyperkalemia, or calcium-phosphate product ≥70

For the renal management of TLS-associated AKI, see AKI nursing. The systemic inflammatory response that can follow severe TLS resembles sepsis — maintain vigilance for secondary infection.

Neutropenic precautions

Leukemia patients — particularly those undergoing induction chemotherapy — develop profound neutropenia as the marrow is suppressed. The absolute neutrophil count (ANC) is the key monitoring parameter:

• ANC <1,000/µL = neutropenia; initiate precautions
• ANC <500/µL = severe neutropenia / profound immunosuppression; highest infection risk

ANC calculation

ANC = WBC × (% bands + % neutrophils) ÷ 100

A patient with WBC 1,500/µL and 30% neutrophils + 5% bands has an ANC of 1,500 × 0.35 = 525/µL — severe neutropenia.

Neutropenic fever: the priority nursing assessment

Temperature ≥38°C (100.4°F) in any patient with ANC <500/µL is a medical emergency.

The patient may have no localizing signs of infection — no cough, no drainage, no induration — because neutrophils mediate the inflammatory response that produces these signs. A single temperature elevation may be the only early clue that the patient is septic. Do not wait for a second temperature. Do not delay for a full assessment before calling the provider.

Nursing response to neutropenic fever:

1. Obtain blood cultures (at least two sets from different sites — one from central line if present, one peripheral) before starting antibiotics
2. Obtain urinalysis and urine culture; chest X-ray
3. Notify provider immediately
4. Anticipate broad-spectrum IV antibiotics (typically piperacillin-tazobactam, cefepime, or meropenem) — initiation should occur within 60 minutes of fever onset
5. Continue monitoring: vital signs every 1–2 hours during acute febrile episode; hemodynamic status (hypotension, tachycardia suggest evolving sepsis)

For the full sepsis recognition and management framework, see sepsis nursing.

Protective precautions (formerly “reverse isolation”)

Current evidence does not support full reverse isolation with positive-pressure rooms as a universal standard for neutropenic patients. However, standard protective measures remain essential and are consistently tested on NCLEX:

• Private room — single-patient room to minimize exposure to airborne pathogens
• Hand hygiene — the most effective single intervention; enforce rigorous hand washing by all staff and visitors before and after patient contact
• No fresh flowers or plants — potting soil and standing water harbor gram-negative bacteria and mold (Aspergillus)
• No raw or unwashed produce — raw fruits and vegetables can carry Pseudomonas and other pathogens; cooked or properly washed produce only
• No ill visitors — screen all visitors for respiratory symptoms or active infection
• Respiratory protection — staff with respiratory illness should not care for neutropenic patients; surgical masks may be worn by visitors per institutional protocol
• Sterile technique for dressing changes and invasive line care
• Meticulous oral care — mucositis creates a portal for bacteremia; chlorhexidine or normal saline rinses per protocol; assess oral mucosa at every assessment

G-CSF (granulocyte colony-stimulating factor): Filgrastim and pegfilgrastim are administered after certain chemotherapy regimens to stimulate marrow recovery and shorten the duration of neutropenia. Nurses administer subcutaneously and monitor CBC. G-CSF causes bone pain (from marrow expansion) — acetaminophen is usually sufficient for management.

NCLEX tips: leukemia

1. Auer rods = AML, never ALL. If a question shows a peripheral blood smear with needle-like cytoplasmic inclusions in blasts, the answer is AML.

2. Smudge cells = CLL. Fragile, crushed lymphocyte nuclei on smear in an older adult with lymphocytosis — think CLL.

3. Philadelphia chromosome is the hallmark of CML (t(9;22) BCR-ABL1). It also occurs in approximately 25% of adult ALL cases. For NCLEX: if CML is the topic, Philadelphia chromosome is the answer. If ALL is the topic and the question specifies adult ALL or poor prognosis, Philadelphia chromosome may also appear.

4. TLS electrolytes: K↑, PO4↑, uric acid↑, Ca↓. All three “hypers” go up; calcium goes down.

5. ANC <500/µL + temperature ≥38°C = notify provider immediately. This is the most important neutropenic fever rule. Do not wait for repeat temperatures.

6. Imatinib (Gleevec) = CML. The first TKI; oral daily medication; revolutionized CML management. On NCLEX, if a question asks about a patient taking imatinib, think CML.

7. Most common leukemia in children = ALL. Most common cancer overall in pediatrics. Cure rate 80–90% in children with modern treatment.

8. Most common leukemia in adults = CLL. Most indolent. Often incidentally diagnosed in an older adult.

9. DIC risk in AML = APL subtype (AML-M3). The abnormal granules in promyelocytes release tissue factor, triggering DIC. ATRA initiated early reduces DIC mortality.

10. Watch-and-wait is appropriate in early CLL (Rai Stage 0). A question that asks what to do for an asymptomatic older adult with absolute lymphocytosis and no organomegaly — the correct answer is observation, not initiating chemotherapy.

11. Blast crisis in CML = ≥20% blasts. The transition from chronic phase to blast crisis transforms CML into an acute leukemia-like emergency. Nursing assessment for increasing fatigue, bone pain, fever, and rapid WBC rise signals phase progression.

12. L-asparaginase in ALL — monitor for pancreatitis. Severe epigastric pain and elevated lipase in an ALL patient on L-asparaginase = hold the drug and notify the provider. Other toxicities: hypersensitivity reactions, coagulopathy, hyperglycemia.

13. No fresh flowers, no raw produce, no ill visitors for neutropenic patients. These are classic NCLEX-style nursing precaution questions.

14. Rasburicase is contraindicated in G6PD deficiency — it causes hemolysis in these patients. Allopurinol is the alternative for G6PD-deficient patients.

Chemotherapy regimens summary

Nursing assessment priorities across leukemia types

Regardless of leukemia type or phase of treatment, the nursing assessment framework centers on the consequences of pancytopenia and the complications specific to each treatment phase.

Every shift assessment:

• Infection: temperature, WBC trend, ANC; assess all body surfaces, mucous membranes, catheter sites; auscultate lungs; assess urinary symptoms; report fever ≥38°C in neutropenic patients without delay
• Bleeding: skin for petechiae, purpura, ecchymosis; mucous membranes for bleeding gums; neurological status (sudden severe headache = intracranial hemorrhage); urine color; stool color; any puncture sites for prolonged oozing
• Anemia: fatigue, pallor, dyspnea on exertion, tachycardia, orthostatic hypotension; hemoglobin and transfusion threshold monitoring
• Organ involvement: splenomegaly (flank pain, early satiety, left upper quadrant tenderness); lymphadenopathy; hepatomegaly (right upper quadrant discomfort, jaundice)
• TLS surveillance during active chemotherapy: electrolytes, renal function, urine output, cardiac rhythm

Patient and family education priorities:

• Infection prevention: hand hygiene, dietary restrictions, avoiding ill contacts, wound care
• Bleeding precautions: soft toothbrush, electric razor, avoid NSAIDs and aspirin, apply pressure to cuts for 10+ minutes, report prolonged bleeding
• Fever response plan: temperature of 38°C (100.4°F) requires immediate medical contact — do not wait to see if it resolves
• Medication adherence (particularly for oral TKI therapy in CML)
• Signs requiring emergency care: severe headache (intracranial bleed), sudden shortness of breath, chest pain, inability to stop bleeding

Summary

Leukemia nursing requires integrating knowledge of four distinct diseases that share a common mechanism — bone marrow replacement — but differ substantially in onset, clinical urgency, treatment approach, and nursing priorities. AML demands vigilance for DIC (in APL), acute TLS, and the profound marrow ablation of the 7+3 induction period. ALL adds CNS prophylaxis, L-asparaginase toxicities, and the management of multi-year chemotherapy in largely pediatric patients. CML is a chronic, outpatient-managed disease requiring TKI adherence support and surveillance for phase progression to blast crisis. CLL tests the nurse’s ability to communicate that watchful waiting is a deliberate, evidence-based treatment choice — and to recognize the abrupt clinical change that signals Richter transformation.

Tumor lysis syndrome and neutropenic fever are the two highest-acuity complications cutting across all leukemia types. Both require rapid recognition and immediate action: aggressive IV hydration and metabolic monitoring for TLS; blood cultures and prompt antibiotics for neutropenic fever.

For related hematologic content, see oncology nursing reference for general chemotherapy care, thrombocytopenia nursing reference for platelet management, and anemia nursing reference for red cell support in hematologic malignancy.